US EditionShares in Wegovy-maker Novo Nordisk pop 6% after GLP-1 pill approval
Novo Nordisk gains a first-mover edge with the FDA-approved oral GLP-1 obesity pill, priced at $149 per month, boosting investor confidence after a challenging year.
- Shares jumped 6% Monday after the U.S. Food and Drug Administration approved oral semaglutide, branded as a Wegovy pill, making it the first oral GLP-1 therapy cleared for obesity.
- After a turbulent year, Novo Nordisk A/S gains a first-mover advantage over Eli Lilly, Pfizer, and others despite board drama, supply shortages, and market-share losses to compounded products and competitors.
- In early January the 1.5 milligram starting dose will be available in pharmacies and select telehealth providers for $149 per month, and cash-paying patients can buy it via TrumpRx under last month's deal.
- Analysts at BMO Capital Markets said the approval lifted investor sentiment but warned it does not resolve Novo Nordisk's longer-term competitive challenges, maintaining a Market Perform rating with a $46 price target.
- Growing oral-GLP1 competition from Structure Therapeutics and Metsera means Eli Lilly's orforglipron is expected in 2026, and analysts flagged a food effect limitation with 2026 clinical and sales catalysts pivotal.
32 Articles
32 Articles
With the approval in the United States of its treatment against obesity in the form of tablets, the Danish laboratory takes a small advantage against its main competitor, Eli Lilly. A welcome respite, but which should be of short duration, for the group losing speedIn the race for treatments against obesity, Novo Nordisk took another step, once again, in the lead. On Tuesday, the Danish pharmaceutical group received the green light from the FDA …
The Novo Nordisk actions recorded a significant increase in March, after the Danish company became the first pharmaceutical producer to obtain FDA approval for a GLP-1 fuel for weight loss. The moment is considered by analysts as a possibility of rehabilitating the company in front of investors, after the weakest year of its history, transmits CNC.
Why Novo Nordisk Stock Popped Today
Key PointsNovo Nordisk's pill could be a convenient new option for adults seeking to lose weight.The worldwide market for weight-loss drugs could grow to a staggering $150 billion in the coming decade.10 stocks we like better than Novo Nordisk › Shares of Novo Nordisk (NYSE: NVO) rose more than 7% on Tuesday after the drugmaker received regulatory approval for its long-awaited GLP-1 pill in the U.S. Image source: Novo Nordisk.Where to invest $1,…
Novo Nordisk has achieved green light to sell in the United States a pill version of his successful Wegovy obesity injection, a crucial step in his effort to defend his market share against his rival Eli Lilly. Novo will start selling the pill on the American market early in January, while Eli Lilly has not yet received approval for a similar pill. The Danish company’s action shoots at 7.5% on the Copenhagen Stock Exchange. Continue reading
Novo Nordisk's shares rose more than 7% this Tuesday, after the Danish pharmaceutical company obtained approval from the U.S. Food and Drug Administration (FDA) for its LPG-1 pill, It is the first in the world of its kind to receive regulatory approval. The authorization gives Novo Nordisk an initial advantage over its American rival Eli Lilly, who also develops an oral drug of the same kind and who has already submitted his application for appr…
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
